Helius Medical Technologies Inc
NASDAQ:HSDT
Helius Medical Technologies Inc
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania. The company went IPO on 2014-06-27. The firm focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The firm's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The firm's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania. The company went IPO on 2014-06-27. The firm focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The firm's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The firm's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.
PIPE Transaction: Solana Company successfully raised over $500 million through a PIPE transaction in September, marking a major strategic shift.
Digital Asset Focus: The company is now focused on a digital asset treasury strategy centered on Solana tokens, with strong backing from Pantera and Summer Capital.
Staking Outperformance: Solana Company's staking program achieved an average yield of 7.03% APY in October, outperforming peer validators.
Financial Results: Reported third quarter revenue of $697,000, driven mainly by $342,000 in staking rewards income.
Large Net Loss: The company posted a net loss of $352.8 million for the third quarter, largely due to derivative and financing costs related to the PIPE transaction.
Strong Treasury: Ended the quarter with $124 million in cash and $350.2 million in digital assets.
Legacy Business: The neurotechnology segment, with its PoNS device, reported clinical progress and increased U.S. activity.
